Florida-based nutraceutical company, Oragenics, Inc. (OTCBB: ORNI) (www.oragenics.com), announced today the issuance of patent number 8,034,571 from the United States Patent and Trademark office for In Vivo Induced Antigen Technology (IVIAT).
This platform technology is a novel approach for studying microbial pathogenesis that identifies genes of a pathogenic organism which are differentially expressed during an actual human infection. IVIAT can be applied to all pathogenic bacteria, yeasts and parasites to rapidly identify proteins that are expressed when a pathogen infects a human. Such proteins are excellent targets for medical diagnostics and therapeutic strategies. We believe that IVIAT is faster, more cost-efficient and significantly more sensitive than competing technologies such as differential proteomics and microarrays. In addition, our technology uses the actual diseased host rather than an animal model, so that biomarkers that we discover are more likely to be of high clinical value.
"IVIAT, and sister technology CMAT™ (Change Mediated Antigen Technology), add tremendous value to our biomarker discovery portfolio," stated Dr. Martin Handfield, Director of Research and Development for Oragenics. "These two technologies could lead to the discovery of new proteins that could be extremely useful in the design of novel diagnostic tests, vaccine targets and antibiotherapy strategies," Dr. Handfield added.
"Oragenics' research in the field of probiotic oral care has led to a pipeline of products ranging from novel anti-infectives to this IVIAT platform technology. Together with our already marketed ProBiora3 and Evora branded probiotics for oral health, we are continuing to build a world-class oral health company," stated Dr. John N. Bonfiglio, President and CEO.
New trials show promise for immune checkpoint blockers in early-stage lung cancer